Mostrar el registro sencillo del ítem
dc.contributor.author | Vart, P. | |
dc.contributor.author | Correa-Rotter, R. | |
dc.contributor.author | Hou, F.F. | |
dc.contributor.author | Jongs, N. | |
dc.contributor.author | Chertow, G.M. | |
dc.contributor.author | Langkilde, A.M. | |
dc.contributor.author | McMurray, J.J.V. | |
dc.contributor.author | Rossing, P. | |
dc.contributor.author | Sjöström, C.D. | |
dc.contributor.author | Stefansson, B.V. | |
dc.contributor.author | Toto, R.D. | |
dc.contributor.author | Douthat, W. | |
dc.contributor.author | Escudero, E. | |
dc.contributor.author | Isidto, R. | |
dc.contributor.author | Khullar, D. | |
dc.contributor.author | Bajaj, H.S. | |
dc.contributor.author | Wheeler, D.C. | |
dc.contributor.author | Heerspink, H.J.L. | |
dc.date.accessioned | 2022-06-01T13:53:57Z | |
dc.date.available | 2022-06-01T13:53:57Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/11732 | |
dc.description.abstract | Introduction: This study aimed to examine the efficacy and safety of dapagliflozin in the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (NCT03036150) by geographic region. Methods: Adults with chronic kidney disease (CKD) with or without type 2 diabetes, with estimated glomerular filtration rate (eGFR) 25 to 75 ml/min per 1.73 m2 and urinary albumin-to-creatinine ratio (UACR) 200 to 5000 mg/g were randomized to dapagliflozin (10 mg once daily) or placebo. The primary end point was a composite of a sustained decline in eGFR of ≥50%, end-stage kidney disease or death from kidney or cardiovascular causes. We categorized recruiting countries into 4 broad global regions: Asia, Europe, Latin America, and North America. Of 4304 randomized patients, 1346 (31.3%) were from Asia, 1233 (28.6%) from Europe, 912 (21.2%) from Latin America, and 813 (18.9%) from North America. Results: The relative risk of the primary composite end point was lower in patients randomized to dapagliflozin (relative to placebo) in all regions, with hazard ratios (95% CI) of 0.70 (0.48–1.00), 0.60 (0.43–0.85), 0.61 (0.43–0.86), and 0.51 (0.34–0.76) among patients from Asia, Europe, Latin America, and North America, respectively. There was no effect modification by region (interaction P = 0.77). Occurrence of serious adverse events (SAEs) was lower among patients randomized to dapagliflozin versus placebo (21.9% vs. 26.8%, 34.1% vs. 38.6%, 29.8% vs. 31.5%, and 34.9% vs. 41.0% in Asia, Europe, Latin America, and North America, respectively). Conclusion: Dapagliflozin reduced kidney and cardiovascular events and prolonged survival in patients with CKD, with and without type 2 diabetes, with no apparent effect modification by geographic region. | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Kidney International Reports | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | dapagliflozin | en_US |
dc.subject | efficacy | en_US |
dc.subject | regions | en_US |
dc.subject | safety | en_US |
dc.subject | SGLT-2 inhibitor | en_US |
dc.title | Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1016/j.ekir.2022.01.1060 | |
dc.relation.issn | 2468-0249 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |